Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...

The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

A collaborative research team has successfully developed a novel fluorescent probe, SLY (Sialyl Lewis Yellow), capable of ...

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine say they have shed new light on the location and function of ...

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and presents a 5-year survival rate of less than 10%. Novel therapies focusing on targeting the tumor ...

Pancreatic ductal adenocarcinoma (PDAC) has long been considered to arise from pancreatic ducts on the basis of its morphology, the occurrence of dysplasia in putative preneoplastic ductal lesions, ...

A Neutrophil Extracellular Trap (NET) associated gene expression signature is identified for Pancreatic Ductal Adenocarcinoma progression. NETS stimulate a CCDC25-ITGB1-ILK mediated signaling ...